Stockscreener 앱 받기
40.27
7.27%
2.73
시장 영업 전:
39.35
-0.92
-2.28%
Apogee Therapeutics Inc 주식(APGE)의 최신 뉴스
Apogee Therapeutics signs manufacturing deal with Samsung Biologics - Investing.com
Apogee Therapeutics IncEnters Master Services Agreement With Samsung Biologics - Marketscreener.com
TD Cowen reiterates buy on Apogee Therapeutics stock - Investing.com India
Strong Buy Recommendation for Apogee Therapeutics Driven by Promising Clinical Data and Strategic Pipeline Developments - TipRanks
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial - AOL
Apogee Therapeutics CEO Michael Henderson sells $301,511 in stock By Investing.com - Investing.com South Africa
Apogee Therapeutics CMO Carl Dambkowski sells $48,463 in stock By Investing.com - Investing.com South Africa
Apogee Therapeutics CMO Carl Dambkowski sells $48,463 in stock - Investing.com
Q1 EPS Estimates for Apogee Therapeutics Reduced by Wedbush - Defense World
Apogee Therapeutics (NASDAQ:APGE) Given Outperform Rating at Wedbush - MarketBeat
New York State Common Retirement Fund Increases Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics (NASDAQ:APGE) Reaches New 1-Year Low After Earnings Miss - Defense World
Apogee Therapeutics: Buy Rating Backed by Promising Data and Strong Financial Position - TipRanks
Where are the Opportunities in (APGE) - Stock Traders Daily
Optimistic Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trial Developments - TipRanks
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by Handelsbanken Fonder AB - Defense World
Apogee Therapeutics (NASDAQ:APGE) Receives “Outperform” Rating from Wedbush - Defense World
Apogee Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results - GlobeNewswire
Jefferies lifts Apogee Therapeutics stock target to $86, maintains buy - Investing.com India
Jefferies lifts Apogee Therapeutics stock target to $86, maintains buy By Investing.com - Investing.com South Africa
Apogee Therapeutics price target raised to $116 from $110 at Guggenheim - TipRanks
Apogee Therapeutics Reports Positive Phase 1 Results - TipRanks
Apogee Therapeutics, Inc. Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG990 - Marketscreener.com
Apogee Therapeutics Full-Year Loss Widens -March 03, 2025 at 06:56 am EST - Marketscreener.com
Apogee Therapeutics, Inc. SEC 10-K Report - TradingView
Apogee Therapeutics Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer Trial - Marketscreener.com
Apogee Therapeutics Advances Clinical Pipeline for APG777 and APG279, Reports Strong Cash Position and 2024 Financial Results - Nasdaq
Can Apogee's Overenrolled Clinical Trial Fast-Track Its Challenge to DUPIXENT? - StockTitan
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy - The Bakersfield Californian
Apogee Therapeutics Announces Positive Interim Phase 1 - GlobeNewswire
Could Apogee's New Antibody End Monthly Injections for Chronic Inflammation Patients? - StockTitan
Rhumbline Advisers Has $2.39 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives $89.71 Average PT from Analysts - Defense World
Apogee Therapeutics (APGE) to Release Earnings on Tuesday - Defense World
Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now? - Insider Monkey
Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives $89.71 Average Target Price from Brokerages - MarketBeat
Apogee Therapeutics to Host Conference Call to Report - GlobeNewswire
Can Apogee's APG990 Clinical Data Transform Its Inflammatory Disease Pipeline? - StockTitan
Apogee Therapeutics (NASDAQ:APGE) Sets New 52-Week LowHere's Why - MarketBeat
1 Biotech Stock to Buy in 2025, and 1 to Avoid - AOL
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%. - AOL
Apogee Therapeutics (APGE) Projected to Post Earnings on Tuesday - MarketBeat
Hims & Hers tumbles 27% as investors fear uncertainty without compounded weight-loss drugs - AOL
Apogee Therapeutics to Participate in Upcoming March Investor Conferences - GlobeNewswire
How Will Apogee Therapeutics Address Investors at March Healthcare Conferences? - StockTitan
(APGE) Trading Report - Stock Traders Daily
Interesting APGE Put And Call Options For October 17th - Nasdaq
Apogee Therapeutics (NASDAQ:APGE) Reaches New 12-Month LowHere's What Happened - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Shares Down 7.1%Here's Why - MarketBeat
Apogee Therapeutics' (APGE) Buy Rating Reaffirmed at Guggenheim - MarketBeat
Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Sells $608,700.00 in Stock - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Stock Price Down 7.1% – What’s Next? - Defense World
2.14%
2.83%
자본화:
|
볼륨(24시간):